English

Lyra Therapeutics, Inc.

EDGAR

LYRA Annual report (10-K) · filed 2026-03-31

Annual consolidated revenue for 2025: about USD 398K, using the latest reported figures. The previous period, 2024, was about USD 1.534M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

7 thousand USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 398000 USD Source
Revenue: 391000 USD Source

Operating margin

-101,685.71%

2025 Q4 · %

Exact inputs and evidence

Operating Income: -31022000 USD Source
Operating Income: -23904000 USD Source
Revenue: 398000 USD Source
Revenue: 391000 USD Source

Operating cash flow

-6.07 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -28859000 USD Source
Operating Cash Flow: -22793000 USD Source

Free cash flow

-6.16 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -28859000 USD Source
Operating Cash Flow: -22793000 USD Source
Capital Expenditure: 116000 USD Source
Capital Expenditure: 20000 USD Source

Cash and cash equivalents: 15.9 million USD 2025-12-31 Source
Exact value

15893000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.77 million shares 2025-12-31 Source
Exact value

1774882 shares

Reported share-count change

35.46% · 465 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1310308 shares · 2024-12-31· Source
1774882 shares · 2025-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

398 thousand USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 183000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 183000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 25000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 398000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 391000 USD · 2025-01-01 – 2025-09-30 Source

Net income

-28.9 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Net income: -8547000 USD · 2025-01-01 – 2025-03-31 Source
Net income: -7437000 USD · 2025-04-01 – 2025-06-30 Source
Net income: -5984000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -28900000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -21968000 USD · 2025-01-01 – 2025-09-30 Source

Operating cash flow

-28.9 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Operating cash flow: -8842000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -15432000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -8842000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -22793000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15432000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -28859000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -22793000 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-03-31.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2025-12-31
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-74.1%

Prior period

USD 1.53 million

2024-01-01 – 2024-12-31
Current period

USD 398,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

398000 − 1534000 = -1136000 USD

1534000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
398000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Year-over-year change in Revenue: -1136000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 398000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2565343 Filing: 000132727326000003 Input fundies:Revenue: 1534000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2567009 Filing: 000132727326000003
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 64.5 million

Prior period

−USD 93.4 million

2024-01-01 – 2024-12-31
Current period

−USD 28.9 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-28900000 − -93400000 = 64500000 USD

-93400000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-28900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Year-over-year change in Net income: 64500000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -28900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#3119661 Filing: 000132727326000003 Input fundies:NetIncome: -93400000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#3120335 Filing: 000132727326000003
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 41.15 million

Prior period

−USD 70.01 million

2024-01-01 – 2024-12-31
Current period

−USD 28.86 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-28859000 − -70011000 = 41152000 USD

-70011000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-28859000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Year-over-year change in Operating cash flow: 41152000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -28859000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2042115 Filing: 000132727326000003 Input fundies:OperatingCashFlow: -70011000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2043970 Filing: 000132727326000003
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-95%

Prior period

USD 2.34 million

2024-01-01 – 2024-12-31
Current period

USD 116,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

116000 − 2338000 = -2222000 USD

2338000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
116000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Year-over-year change in Capital expenditure: -2222000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 116000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2048806 Filing: 000132727326000003 Input fundies:CapitalExpenditure: 2338000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2050545 Filing: 000132727326000003
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 398,000 100% of revenue
Operating costs Derived USD 31.42 million 7,894% of revenue
Operating income −USD 31.02 million −7,794% of revenue
Tax, interest and other Derived −USD 2.12 million −533% of revenue
Net income −USD 28.9 million −7,261% of revenue

Cash

Operating cash flow −USD 28.86 million −7,251% of revenue
Capital expenditure USD 116,000 29% of revenue
Free cash flow Derived −USD 28.98 million −7,280% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 15,404% of revenue.
2022 Operating loss: operating costs were 4,231% of revenue.
2023 Operating loss: operating costs were 4,408% of revenue.
2024 Operating loss: operating costs were 6,381% of revenue.
2025 Operating loss: operating costs were 7,894% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	285000	43900000 Derived	-43615000	-115000 Derived	-43500000	-29205000 Derived	Source 2021-01-01 – 2021-12-31: 285000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -43615000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -43500000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -25820000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3385000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1363000	57669000 Derived	-56306000	-1006000 Derived	-55300000	-43549000 Derived	Source 2022-01-01 – 2022-12-31: 1363000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -56306000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -55300000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -43385000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 164000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1558000	68678000 Derived	-67120000	-4420000 Derived	-62700000	-64351000 Derived	Source 2023-01-01 – 2023-12-31: 1558000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -67120000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -62700000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -63304000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1047000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1534000	97882000 Derived	-96348000	-2948000 Derived	-93400000	-72349000 Derived	Source 2024-01-01 – 2024-12-31: 1534000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -96348000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -93400000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -70011000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 2338000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	398000	31420000 Derived	-31022000	-2122000 Derived	-28900000	-28975000 Derived	Source 2025-01-01 – 2025-12-31: 398000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -31022000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -28900000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -28859000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 116000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 398K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	285000	Revenue: 285000 Open source
20222022-12-31	Revenue	1363000	Revenue: 1363000 Open source
20232023-12-31	Revenue	1558000	Revenue: 1558000 Open source
20242024-12-31	Revenue	1534000	Revenue: 1534000 Open source
20252025-12-31	Revenue	398000	Revenue: 398000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-74.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 285000 Open source
20222022-12-31	Year over year	378.2%	Revenue: 1363000 Open source Revenue: 285000 Open source
20232023-12-31	Year over year	14.3%	Revenue: 1558000 Open source Revenue: 1363000 Open source
20242024-12-31	Year over year	-1.5%	Revenue: 1534000 Open source Revenue: 1558000 Open source
20252025-12-31	Year over year	-74.1%	Revenue: 398000 Open source Revenue: 1534000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -7,794.5% 2025

Net margin -7,261.3% 2025

Free cash flow margin -7,280.2% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-15,303.5%	Operating Income: -43615000 Open source Revenue: 285000 Open source
20222022-12-31	Operating margin	-4,131%	Operating Income: -56306000 Open source Revenue: 1363000 Open source
20232023-12-31	Operating margin	-4,308.1%	Operating Income: -67120000 Open source Revenue: 1558000 Open source
20242024-12-31	Operating margin	-6,280.8%	Operating Income: -96348000 Open source Revenue: 1534000 Open source
20252025-12-31	Operating margin	-7,794.5%	Operating Income: -31022000 Open source Revenue: 398000 Open source
20212021-12-31	Net margin	-15,263.2%	Net Income: -43500000 Open source Revenue: 285000 Open source
20222022-12-31	Net margin	-4,057.2%	Net Income: -55300000 Open source Revenue: 1363000 Open source
20232023-12-31	Net margin	-4,024.4%	Net Income: -62700000 Open source Revenue: 1558000 Open source
20242024-12-31	Net margin	-6,088.7%	Net Income: -93400000 Open source Revenue: 1534000 Open source
20252025-12-31	Net margin	-7,261.3%	Net Income: -28900000 Open source Revenue: 398000 Open source
20212021-12-31	Free cash flow margin	-10,247.4%	Revenue: 285000 Open source Operating Cash Flow: -25820000 Open source Capital Expenditure: 3385000 Open source
20222022-12-31	Free cash flow margin	-3,195.1%	Revenue: 1363000 Open source Operating Cash Flow: -43385000 Open source Capital Expenditure: 164000 Open source
20232023-12-31	Free cash flow margin	-4,130.4%	Revenue: 1558000 Open source Operating Cash Flow: -63304000 Open source Capital Expenditure: 1047000 Open source
20242024-12-31	Free cash flow margin	-4,716.4%	Revenue: 1534000 Open source Operating Cash Flow: -70011000 Open source Capital Expenditure: 2338000 Open source
20252025-12-31	Free cash flow margin	-7,280.2%	Revenue: 398000 Open source Operating Cash Flow: -28859000 Open source Capital Expenditure: 116000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -28.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-25820000	Operating Cash Flow: -25820000 Open source
20222022-12-31	Operating cash flow	-43385000	Operating Cash Flow: -43385000 Open source
20232023-12-31	Operating cash flow	-63304000	Operating Cash Flow: -63304000 Open source
20242024-12-31	Operating cash flow	-70011000	Operating Cash Flow: -70011000 Open source
20252025-12-31	Operating cash flow	-28859000	Operating Cash Flow: -28859000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -29M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-29205000	Operating Cash Flow: -25820000 Open source Capital Expenditure: 3385000 Open source
20222022-12-31	Free cash flow	-43549000	Operating Cash Flow: -43385000 Open source Capital Expenditure: 164000 Open source
20232023-12-31	Free cash flow	-64351000	Operating Cash Flow: -63304000 Open source Capital Expenditure: 1047000 Open source
20242024-12-31	Free cash flow	-72349000	Operating Cash Flow: -70011000 Open source Capital Expenditure: 2338000 Open source
20252025-12-31	Free cash flow	-28975000	Operating Cash Flow: -28859000 Open source Capital Expenditure: 116000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

129.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	37.5%	Total Liabilities: 20551000 Open source Total Assets: 54867000 Open source
20222022-12-31	Liabilities / assets	26.6%	Total Liabilities: 29214000 Open source Total Assets: 109968000 Open source
20232023-12-31	Liabilities / assets	37.3%	Total Liabilities: 53180000 Open source Total Assets: 142600000 Open source
20242024-12-31	Liabilities / assets	82.5%	Total Liabilities: 54752000 Open source Total Assets: 66346000 Open source
20252025-12-31	Liabilities / assets	129.7%	Total Liabilities: 46825000 Open source Total Assets: 36108000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.71× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	2.63×	Current Assets: 47918000 Open source Current Liabilities: 18246000 Open source
20222022-12-31	Current assets / current liabilities	6.97×	Current Assets: 100829000 Open source Current Liabilities: 14470000 Open source
20232023-12-31	Current assets / current liabilities	5.35×	Current Assets: 104821000 Open source Current Liabilities: 19597000 Open source
20242024-12-31	Current assets / current liabilities	3.41×	Current Assets: 43025000 Open source Current Liabilities: 12631000 Open source
20252025-12-31	Current assets / current liabilities	1.71×	Current Assets: 16272000 Open source Current Liabilities: 9522000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 16.31 million Exact value Exact value: -16306000 USD 2019-01-01 – 2019-12-31: -16306000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2019-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -16306000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16306000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459021011767/lyra-20201231.xml#91227 Filing: 000156459021011767 The citation records this snapshot. The page link may show a newer release later.	−USD 13.75 million Exact value Exact value: -13754000 USD 2019-01-01 – 2019-12-31: -13754000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2019-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -13754000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13754000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459021011767/lyra-20201231.xml#110995 Filing: 000156459021011767 The citation records this snapshot. The page link may show a newer release later.	USD 211,000 Exact value Exact value: 211000 USD 2019-01-01 – 2019-12-31: 211000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2019-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 211000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 211000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459021011767/lyra-20201231.xml#111417 Filing: 000156459021011767 The citation records this snapshot. The page link may show a newer release later.	−USD 13.97 million Calculation and evidence -13754000 − 211000 USD Exact free cash flow: -13965000 USD 2019-01-01 – 2019-12-31: -13754000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 211000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2019-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -13965000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13754000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459021011767/lyra-20201231.xml#110995 Filing: 000156459021011767 Input fundies:CapitalExpenditure: 211000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459021011767/lyra-20201231.xml#111417 Filing: 000156459021011767 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 22.1 million Exact value Exact value: -22100000 USD 2020-01-01 – 2020-12-31: -22100000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2020-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -22100000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22100000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-10k_20211231.htm#3118903 Filing: 000156459022009187 The citation records this snapshot. The page link may show a newer release later.	−USD 21.14 million Exact value Exact value: -21143000 USD 2020-01-01 – 2020-12-31: -21143000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2020-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -21143000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21143000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-10k_20211231.htm#2671941 Filing: 000156459022009187 The citation records this snapshot. The page link may show a newer release later.	USD 1.78 million Exact value Exact value: 1775000 USD 2020-01-01 – 2020-12-31: 1775000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2020-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 1775000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1775000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-10k_20211231.htm#2679681 Filing: 000156459022009187 The citation records this snapshot. The page link may show a newer release later.	−USD 22.92 million Calculation and evidence -21143000 − 1775000 USD Exact free cash flow: -22918000 USD 2020-01-01 – 2020-12-31: -21143000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1775000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2020-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -22918000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21143000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-10k_20211231.htm#2671941 Filing: 000156459022009187 Input fundies:CapitalExpenditure: 1775000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000156459022009187/lyra-10k_20211231.htm#2679681 Filing: 000156459022009187 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 43.5 million Exact value Exact value: -43500000 USD 2021-01-01 – 2021-12-31: -43500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2021-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -43500000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-20221231.htm#4000118 Filing: 000095017023010632 The citation records this snapshot. The page link may show a newer release later.	−USD 25.82 million Exact value Exact value: -25820000 USD 2021-01-01 – 2021-12-31: -25820000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2021-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -25820000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25820000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-20221231.htm#3199463 Filing: 000095017023010632 The citation records this snapshot. The page link may show a newer release later.	USD 3.39 million Exact value Exact value: 3385000 USD 2021-01-01 – 2021-12-31: 3385000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2021-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 3385000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3385000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-20221231.htm#3207365 Filing: 000095017023010632 The citation records this snapshot. The page link may show a newer release later.	−USD 29.21 million Calculation and evidence -25820000 − 3385000 USD Exact free cash flow: -29205000 USD 2021-01-01 – 2021-12-31: -25820000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3385000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2021-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -29205000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25820000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-20221231.htm#3199463 Filing: 000095017023010632 Input fundies:CapitalExpenditure: 3385000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017023010632/lyra-20221231.htm#3207365 Filing: 000095017023010632 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 55.3 million Exact value Exact value: -55300000 USD 2022-01-01 – 2022-12-31: -55300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2022-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -55300000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55300000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-20231231.htm#3321382 Filing: 000095017024035047 The citation records this snapshot. The page link may show a newer release later.	−USD 43.39 million Exact value Exact value: -43385000 USD 2022-01-01 – 2022-12-31: -43385000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2022-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -43385000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43385000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-20231231.htm#2487957 Filing: 000095017024035047 The citation records this snapshot. The page link may show a newer release later.	USD 164,000 Exact value Exact value: 164000 USD 2022-01-01 – 2022-12-31: 164000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2022-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 164000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 164000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-20231231.htm#2492728 Filing: 000095017024035047 The citation records this snapshot. The page link may show a newer release later.	−USD 43.55 million Calculation and evidence -43385000 − 164000 USD Exact free cash flow: -43549000 USD 2022-01-01 – 2022-12-31: -43385000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 164000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2022-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -43549000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43385000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-20231231.htm#2487957 Filing: 000095017024035047 Input fundies:CapitalExpenditure: 164000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017024035047/lyra-20231231.htm#2492728 Filing: 000095017024035047 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 62.7 million Exact value Exact value: -62700000 USD 2023-01-01 – 2023-12-31: -62700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2023-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -62700000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62700000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038751/lyra-20241231.htm#4202764 Filing: 000095017025038751 The citation records this snapshot. The page link may show a newer release later.	−USD 63.3 million Exact value Exact value: -63304000 USD 2023-01-01 – 2023-12-31: -63304000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2023-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -63304000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -63304000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038751/lyra-20241231.htm#3145540 Filing: 000095017025038751 The citation records this snapshot. The page link may show a newer release later.	USD 1.05 million Exact value Exact value: 1047000 USD 2023-01-01 – 2023-12-31: 1047000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2023-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 1047000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1047000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038751/lyra-20241231.htm#3151195 Filing: 000095017025038751 The citation records this snapshot. The page link may show a newer release later.	−USD 64.35 million Calculation and evidence -63304000 − 1047000 USD Exact free cash flow: -64351000 USD 2023-01-01 – 2023-12-31: -63304000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1047000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2023-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -64351000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -63304000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038751/lyra-20241231.htm#3145540 Filing: 000095017025038751 Input fundies:CapitalExpenditure: 1047000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038751/lyra-20241231.htm#3151195 Filing: 000095017025038751 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 93.4 million Exact value Exact value: -93400000 USD 2024-01-01 – 2024-12-31: -93400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2024-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -93400000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -93400000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#3120335 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	−USD 70.01 million Exact value Exact value: -70011000 USD 2024-01-01 – 2024-12-31: -70011000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2024-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -70011000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70011000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2043970 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	USD 2.34 million Exact value Exact value: 2338000 USD 2024-01-01 – 2024-12-31: 2338000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2024-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 2338000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2338000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2050545 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	−USD 72.35 million Calculation and evidence -70011000 − 2338000 USD Exact free cash flow: -72349000 USD 2024-01-01 – 2024-12-31: -70011000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 2338000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2024-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -72349000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70011000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2043970 Filing: 000132727326000003 Input fundies:CapitalExpenditure: 2338000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2050545 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 28.9 million Exact value Exact value: -28900000 USD 2025-01-01 – 2025-12-31: -28900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Net Income: -28900000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28900000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#3119661 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	−USD 28.86 million Exact value Exact value: -28859000 USD 2025-01-01 – 2025-12-31: -28859000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Operating Cash Flow: -28859000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28859000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2042115 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	USD 116,000 Exact value Exact value: 116000 USD 2025-01-01 – 2025-12-31: 116000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Capital Expenditure: 116000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 116000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2048806 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.	−USD 28.98 million Calculation and evidence -28859000 − 116000 USD Exact free cash flow: -28975000 USD 2025-01-01 – 2025-12-31: -28859000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 116000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lyra Therapeutics, Inc. · 2025-12-31 Lyra Therapeutics, Inc. (edgar:1327273) Free cash flow: -28975000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T11:40:04Z Snapshot: 73d6637b92e1a88a42f49b787b461e040935dce393d9bbeaba0f310a3b09b765 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1327273?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28859000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2042115 Filing: 000132727326000003 Input fundies:CapitalExpenditure: 116000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1327273/000132727326000003/lyra-20251231.htm#2048806 Filing: 000132727326000003 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

36 filings · 1,529 latest values · 1,529 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001327273, 1327273, LYRA, edgar:1327273

Also known as 480 Biomedical, Inc., Arsenal Medical, Inc., Arsenal Vascular, Inc., Lyra Therapeutics, Inc., WMR Biomedical Inc

Lyra Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation